Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis

BMC Immunology

Table 3 Univariate and multivariate logistic regression analysis of related factors of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)

	Univariate logistic analysis		Multivariate logistic analysis
	OR (95% CI)	P value	OR (95% CI)	P value
sPD-1	1.00 (1.00–1.01)	0.008*	1.012 (1.002–1.023)	0.020*
Age	1.05 (0.99–1.10)	0.073
Female	0.27 (0.08–0.88)	0.029*	0.135 (0.005–3.981)	0.246
Disease duration	1.00 (0.95–1.06)	0.977
Smoking history	9.77 (1.22–78.14)	0.032*	2.35 (0.042–130.83)	0.677
DAS28-ESR	1.05 (0.77–1.44)	0.768
Sharp score	0.86 (0.69–1.07)	0.171
Anti-CCP positive	8.75 (1.69–45.44)	0.029*	10.601 (0.602–186.681)	0.107
Anti-CCP titer	1.00 (1.00–1.01)	0.014*	1.001 (0.999–1.003)	0.587
RF positive	1.94 (0.59–6.41)	0.278
RF titer	1.00 (0.99–1.01)	0.175
Ferritin	1.00 (0.99–1.01)	0.641
Use of biologics	5.71 (0.70–47.01)	0.105
Use of MTX	0.13 (0.05–0.34)	< 0.0001*	0.052 (0.009–0.292)	0.0008*
Use of GCs	2.61 (1.01–6.73)	0.047*	6.517 (0.588–72.206)	0.127
Dose of GCs	1.06 (1.01–1.12)	0.021*	1.024 (0.927–1.131)	0.637

sPD-1 soluble programmed death molecule-1, DAS28 disease activity score using 28 joint counts, anti-CCP anticitrullinated peptide antibody, RF rheumatoid factor, MTX methotrexate, GCs glucocorticoids (in prednisolone equivalent)
–: NA; *P < 0.05

ISSN: 1471-2172